Abstract
We characterized the pharmacokinetic profile of imipenem-cilastatin administered intravenously to six normal volunteers in a dose of 1,000 mg of each drug every 6 h for 40 doses. The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively. The central compartment volumes of distribution for imipenem and cilastatin were 0.16 (+/- 0.05) and 0.14 (+/- 0.03) liter/kg, respectively. Elimination half-lives were short: 0.93 (+/- 0.09) h for imipenem and 0.84 (+/- 0.11) h for cilastatin. Plasma clearances were 12.1 (+/- 0.06) liters/h per 1.73 m2 for imipenem and 12.4 (+/- 1.1) liters/h per 1.73 m2 for cilastatin. Renal clearance accounted for 54% of the plasma clearance of imipenem and 69% of the plasma clearance of cilastatin. The concentrations of imipenem in plasma and urine remained above the MICs of the vast majority of pathogens throughout the dosing interval.
MeSH Terms
Adult
Anti-Bacterial Agents/metabolism
Cilastatin
Cyclopropanes/metabolism,urine
Drug Administration Schedule
Drug Combinations
Half-Life
Humans
Imipenem
Injections, Intravenous
Kinetics
Male
Thienamycins/metabolism,urine
Chemicals
Anti-Bacterial Agents
Cyclopropanes
Drug Combinations
Thienamycins
Cilastatin
Imipenem
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Drusano G L
Standiford H C
Bustamante C
Forrest A
Rivera G
Leslie J
Tatem B
Delaportas D
MacGregor R R
Schimpff S C
References (9)
9 references, click to expand
-
A program package for simulation and parameter estimation in pharmacokinetic systems.
Comput Programs Biomed. 1979 Mar;9(2):115-34
PMID: 761456
-
In vitro activity of N-formimidoyl thienamycin (MK0787).
Antimicrob Agents Chemother. 1980 Oct;18(4):642-4
PMID: 6934708
-
In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.
Antimicrob Agents Chemother. 1981 Jan;19(1):114-6
PMID: 6787975
-
In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
Antimicrob Agents Chemother. 1981 Feb;19(2):248-52
PMID: 6214986
-
Disposition of radiolabeled imipenem and cilastatin in normal human volunteers.
Antimicrob Agents Chemother. 1984 Nov;26(5):707-14
PMID: 6595962
-
Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.
Antimicrob Agents Chemother. 1983 Feb;23(2):293-9
PMID: 6573156
-
Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.
Antimicrob Agents Chemother. 1983 Feb;23(2):300-7
PMID: 6573157
-
Thienamycin: development of imipenen-cilastatin.
J Antimicrob Chemother. 1983 Dec;12 Suppl D:1-35
PMID: 6365872
-
Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.
Antimicrob Agents Chemother. 1982 Jul;22(1):62-70
PMID: 7125632